Alvotech and Teva get US FDA approval of Selarsdi
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Highly effective preservation solutions ensuring the safety and protection of personal care products
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
Application based on results from the TROPION-Breast01 Phase III trial
Under this agreement, lpca will grant to Omexa a non-exclusive right to research, develop, manufacture and market an anti-cancer biosimilar for the global market
WINREVAIR is a breakthrough biologic for this rare, progressive disease
New Bioprocessing Production Center in Daejeon to supply products to customers in Asia-Pacific for development and production of biologics
To accelerate the development of next-generation radioconjugates to treat cancer
Subscribe To Our Newsletter & Stay Updated